Hengrui Medicine to eliminate supervisory board, expand business scope

Jiangsu Hengrui Medicine's board of directors approved amendments to its Articles of Association on December 10, 2025. The changes include expanding the company's business scope to include the research, manufacturing, and sale of pharmaceutical packaging materials and products, subject to market regulator approval. This update aligns with the company's operational development needs.

A key revision is the proposed elimination of the supervisory board and its related roles. The board's audit committee will assume the supervisory responsibilities previously held by the supervisory board, in accordance with "Company Law" and other relevant regulations. Until shareholders approve this change, the ninth supervisory board will continue its oversight duties.

The company's registered capital has been updated to RMB 6,637,199,874. Following its initial public offering of H-shares, the total number of ordinary shares stands at 6,637,199,874, with A-shares comprising 6,379,002,274 shares (96.11% of total share capital) and H-shares totaling 258,197,600 shares (3.89%). These amendments are subject to shareholder approval and final market regulatory clearance.